Angiosarcoma Clinical Presentation
- Author: Belen Carsi, MD, PhD, FRCS; Chief Editor: Dirk M Elston, MD more...
Angiosarcomas are insidious, and they may not produce symptoms until the disease is well advanced. History should focus on identifying risk factors; however, most patients do not have these factors.
Risk factors are as follows:
Toxic exposure or radiation therapy
Other carcinogens (eg, bone wax, Dacron, metal bodies)
Angiosarcomas arising at different sites and in different organs have some distinct features, but the clinical manifestations they cause are associated with the amount of organ tissue replaced, as follows:
The etiology of most cases of angiosarcoma is unknown. The tumors may develop as a complication of a preexisting condition. The following factors may be associated with tumor development[14, 11] :
Preexisting benign lesions (eg, bone infarct, pagetoid bone, chronic osteomyelitis)
Chronic lymphedema is the most widely recognized risk factor, especially in angiosarcomas of the skin and soft tissue. Typically, lymphedema-associated angiosarcomas occur in women who have undergone radical mastectomy for breast carcinoma and have had chronic lymphedema for many years (Stewart-Treves syndrome) or in the leg of patients as a consequence of radical inguinal lymphadenectomy for metastases from malignant melanoma (Kettles syndrome).
Chronic lymphedema occurring on a congenital, idiopathic, traumatic, or infectious basis also predisposes to angiosarcoma. The rationale for this association is the status of immunologic privilege of a lymphedematous region.
The lesion arises in the area of previous radiation, with an interval between irradiation and the development of the new tumor of approximately 10 years. The risk of postradiotherapy sarcomas appears to augment with increasing dosage.
The diagnosis mandates that the lesion must have proven histologic differences from the primary neoplasm (carcinomas, lymphomas). Angiosarcomas of bone arising in a previously radiated bone are third in frequency after osteosarcoma and fibrosarcoma. Angiosarcoma of soft tissue is the first diagnosis in soft tissue sarcomas arising within the field of radiation, followed by malignant fibrous histiocytoma (MFH).
The Finnish Cancer registry suggests that although an increased risk of angiosarcoma in cancer patients is evident, especially with breast and gynecologic cancer, the excess does not appear to be strongly related to radiotherapy. Contrary to this finding, based on 135 soft-tissue sarcomas identified in 194,798 women in the SEER database, Huang and Mackillop reported a 16-fold increased risk (95% CI, 6.6-38.0) of angiosarcoma (based on 27 cases) and a 2-fold increased risk (95% CI, 1.4-3.3) of other sarcomas in breast cancer patients who had received radiation therapy, compared to those who had not.
Some angiosarcomas are associated with foreign material introduced in the body, either iatrogenically or accidentally. This association is described with the following materials:
Plastic graft material
Vintners who spray vines against mildew and patients with psoriases given prolonged treatment with Fowler solution (1% potassium arsenite) are at risk. Exposure to arsenic may increase the risk of angiosarcoma of the liver.
Dioxin, a contaminant of industrial processes, is a controversial risk factor associated with the development of soft tissue sarcomas. Likewise, exposure to vinyl chloride used in polymerization in the plastic industry can lead to angiosarcomas of liver and soft tissue.
Physical examination findings often are unremarkable; however, subtle findings may provide clues to early detection.
Angiosarcoma of soft tissue
Patients with soft-tissue angiosarcomas[6, 12] usually present with a moderately paced growing mass in the extremities; the rapid progression of the disease is sometimes the clue to the diagnosis. Soft-tissue angiosarcomas may also develop in the retroperitoneum or abdominal wall.
Retroperitoneal angiosarcomas usually present as asymptomatic masses and generally grow to large sizes because the abdomen can accommodate tumors. Patients may present with neurologic symptoms from compression of lumbar or pelvic nerves.
Approximately 33% of patients have evidence of recent hemorrhage or coagulopathy, including anemia, persistent hematoma, hemothorax, hemorrhagic ascites, and gastrointestinal bleeding. Frequently, the adjacent nodes are enlarged; the incidence rate of node metastasis is as high as 45%
Angiosarcoma of bone
Angiosarcoma of bone can affect any portion of the skeleton, although 33% of these tumors occur in the axial skeleton, 33% in long tubular bones, and the rest in the small bones of the hands and feet. These tumors can be multifocal, affecting the same bone with multiple lesions, or multicentric, involving multiple bones of the same extremity. The patients do not present specific symptoms, although pain is common and the area is frequently tender.
Sometimes, swelling and increased size of the affected limb due to affectation of a superficial bone or to soft tissue extension characterize the presentation. Pathologic fractures occur in 10% of patients.
Four variants of cutaneous angiosarcoma are currently recognized, as follows[20, 14] :
Angiosarcoma of the scalp and face
Angiosarcoma in the context of lymphedema (Stewart-Treves syndrome)
Angiosarcoma of the scalp and face
This is the most common form of angiosarcoma. The disease is primarily located on the head and neck, and usually occurs in elderly persons; it is also known as Wilson-Jones angiosarcoma, senile angiosarcoma, or malignant angioendothelioma.
Most patients present with an enlarging bruise, a blue-black nodule, or an unhealed ulceration. Initially, these lesions can be confused with cellulitis, edema, bruising, or infection, leading to a delay in diagnosis. Bleeding and pain may be present. The clinical pattern of the lesions may be nodular, diffuse, or ulcerated.
Cutaneous angiosarcoma associated with lymphedema
Lymphedema -associated angiosarcoma (LAS) was first reported in six patients with postmastectomy lymphedema. In each case, angiosarcoma developed in the ipsilateral arm and occurred several years after mastectomy. Subsequently, LAS was reported after axillary node dissection for melanoma and in the context of congenital lymphedema, filarial lymphedema, and chronic idiopathic lymphedema. The risk for developing LAS 5 years after mastectomy is approximately 5%. The most common site is the medial aspect of the upper arm. LAS presents as a violaceous plaque or nodule superimposed on brawny, nonpitting edema. Ulceration may develop rapidly.
These lesions occur in the radiation field 4-40 years after irradiation. Exposure to Thorotrast (a radioactive radiographic contrast agent used in the United States until the 1950s) may lead many years later to liver angiosarcoma.
This is a rare, recently described variant with an aggressive course. Death occurs 2-3 years after presentation.
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010 Oct. 11(10):983-91. [Medline].
Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC. Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol. 2010 Apr 1. 101(5):401-7. [Medline].
Babarovic E, Zamolo G, Mustac E, Strcic M. High grade angiosarcoma arising in fibroadenoma. Diagn Pathol. 2011 Dec 20. 6(1):125. [Medline].
Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol. 2003 May. 15(3):239-52. [Medline].
Soft Tissue Tumors. Enzinger FM, Weiss SW, eds. Soft Tissue Tumors. 3rd ed. St. Louis, Mo: Mosby; 1995. 648-77.
Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006 Dec 15. 119(12):2922-30. [Medline].
Adami H, Hunter D, Trichopoulos D, eds. Textbook of Cancer Epidemiology. 2nd ed. Oxford University Press; 2008.
Lezama-del Valle P, Gerald WL, Tsai J, et al. Malignant vascular tumors in young patients. Cancer. 1998 Oct 15. 83(8):1634-9. [Medline].
Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996 Jun 1. 77(11):2400-6. [Medline].
Schottenfeld D, Fraumeni J, eds. Cancer. Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006. 763-786/959-974.
Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol. 1998 Jun. 22(6):683-97. [Medline].
Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010 Jun. 251(6):1098-106. [Medline].
DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008.
Virtanen A, Pukkala E, Auvinen A. Angiosarcoma after radiotherapy: a cohort study of 332 163 Finnish cancer patients. The British Journal of Cancer. Jul 2007. 97:115. [Medline].
Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am J Surg Pathol. 2008 Jun. 32(6):943-50. [Medline].
Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001. Jul 1;92(1):172-80. [Medline].
USA: National Cancer Institute (NCI); 2000-2004. The Surveillance, Epidemiology, and End Results (SEER) Program. Available at http://seer.cancer.gov/.
Wenger DE, Wold LE. Malignant vascular lesions of bone: radiologic and pathologic features. Skeletal Radiol. 2000 Nov. 29(11):619-31. [Medline].
Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004 Jun. 50(6):867-74. [Medline].
Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. Apr 2007. 13(7):2128-35. [Medline].
[Guideline] NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Available at https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Version 2.2016; Accessed: June 1, 2016.
Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012. 17(2):260-6. [Medline]. [Full Text].
Ravi V, Sanford EM, Wang WL, Ross JS, Ramesh N, Futreal A, et al. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. J Natl Compr Canc Netw. 2016 May. 14 (5):499-502. [Medline].
Budd GT. Management of Angiosarcoma. Curr Oncol Rep. 2002. 4(6):515-519. [Medline].
Pasquier E, André N, Street J, Chougule A, Rekhi B, Ghosh J, et al. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. EBioMedicine. 2016 Apr. 6:87-95. [Medline]. [Full Text].
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005 Jul 15. 104(2):361-6. [Medline].
Vogt T, Hafner C, Bross K, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamidein patients with advanced malignant vascular tumors. Cancer. 2003 Nov 15. 98(10):2251-6. [Medline].
Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int J Cancer. 2001 Apr 15. 92(2):161-7. [Medline].